 CRANBURY, N.J., Dec. 01, 2020 GLOBE NEWSWIRE -- Rafael Pharmaceuticals, Inc. Rafael or the Company, a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613 devimistat in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. In partnership with Saras Cure and Sarcoma Alliance for Research through Collaboration SARC, Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States. 